FDA Inspection 1256361 — Zhejiang Novus Pharmaceuticals Co., Ltd.
The FDA completed an inspection of Zhejiang Novus Pharmaceuticals Co., Ltd. on Nov 8, 2024 in Shaoxing. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Nov 8, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Shaoxing (China)